Retatrutide Clinical Trial Results 2026: Latest Data

Eli Lilly's retatrutide has generated substantial attention in metabolic medicine based on clinical trial results published since 2023. As Phase 3 trials progress through 2026, the data continues to support retatrutide's position as potentially the most effective weight loss medication in development. Here's what the clinical evidence shows.

Phase 2 Trial: The Foundation

The Phase 2 trial results, published in the New England Journal of Medicine in June 2023, established retatrutide's efficacy profile. This randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity (BMI 30 or greater) or overweight (BMI 27-29.9) with at least one weight-related condition.

Participants received weekly subcutaneous injections at various doses ranging from 1mg to 12mg, or placebo. The primary endpoint was percentage change in body weight from baseline at 24 weeks, with extended observation through 48 weeks.

Weight Loss Results

At 48 weeks, weight loss varied by dose:

• Placebo: 2.1% weight loss
• Retatrutide 1mg: 8.7% weight loss
• Retatrutide 4mg: 17.1% weight loss
• Retatrutide 8mg: 22.8% weight loss
• Retatrutide 12mg: 24.2% weight loss

The 24% weight loss at the highest dose exceeded results seen with any previously tested weight loss medication. More than 90% of participants receiving 8mg or 12mg doses achieved at least 5% weight loss—the threshold typically considered clinically meaningful.

Metabolic Improvements

Beyond weight loss, trial participants showed improvements across multiple cardiometabolic parameters:

• HbA1c reductions averaging 0.5 percentage points in non-diabetic participants
• Systolic blood pressure reductions of 8-10 mmHg in higher-dose groups
• Triglyceride reductions exceeding 30%
• LDL cholesterol reductions of approximately 15%
• Liver fat content reductions (measured by MRI) exceeding 50% in subset analyses

Phase 2 Diabetes Trial

A parallel Phase 2 trial examined retatrutide specifically in patients with type 2 diabetes. Published results showed HbA1c reductions of up to 2.0 percentage points—among the largest reductions seen with any glucose-lowering medication. Weight loss in the diabetic population slightly trailed the non-diabetic cohort, consistent with patterns seen with other GLP-1 medications.

The combination of substantial glucose control and significant weight loss positions retatrutide as a potential treatment for type 2 diabetes that addresses both the metabolic dysfunction and the underlying obesity that often drives disease progression.

Phase 3 Trials: Current Status

Eli Lilly launched multiple Phase 3 trials under the TRIUMPH program name. These larger, longer-duration studies will generate the data necessary for regulatory submission. As of early 2026, key trials include:

TRIUMPH-1: Obesity Without Diabetes

This trial enrolls approximately 1,800 adults with obesity but without type 2 diabetes. The primary endpoint is weight change at 72 weeks, providing longer-term efficacy and safety data than Phase 2 allowed. Results are expected in late 2026.

TRIUMPH-2: Type 2 Diabetes

Focused on patients with type 2 diabetes and overweight or obesity, this trial examines both glycemic control and weight loss as co-primary endpoints. The diabetic population often presents greater treatment challenges, making these results particularly important for establishing retatrutide's role in diabetes management.

TRIUMPH-3: MASH/Fatty Liver

Given the pronounced liver fat reductions observed in Phase 2, a dedicated trial examines retatrutide in patients with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). This trial uses histological endpoints—liver biopsy changes—rather than imaging alone, the gold standard for demonstrating therapeutic benefit in fatty liver disease.

Safety Profile Analysis

Phase 2 safety data showed an adverse event profile similar to existing GLP-1 medications. Gastrointestinal events were most common:

• Nausea: 25-45% depending on dose (mostly mild to moderate)
• Diarrhea: 15-25%
• Vomiting: 10-20%
• Constipation: 10-15%

Most gastrointestinal symptoms occurred during dose escalation and diminished over time. Discontinuation rates due to adverse events remained comparable to other GLP-1 class medications, suggesting tolerability aligns with established treatments.

The theoretical concern about glucagon-mediated hyperglycemia did not materialize in trial data. Fasting glucose and HbA1c improved across all dose groups, indicating the GLP-1 and GIP components adequately counterbalance any glucagon effect on blood sugar.

Comparison with Existing Medications

While direct head-to-head trials haven't been conducted, cross-trial comparisons suggest retatrutide's efficacy exceeds both semaglutide and tirzepatide. Key observations:

• 24% weight loss vs. approximately 22% with tirzepatide 15mg
• 24% weight loss vs. approximately 17% with semaglutide 2.4mg
• Greater liver fat reduction than reported with other GLP-1 medications
• Comparable glycemic improvements to tirzepatide in diabetic populations

Timeline to Approval

Based on current trial timelines and regulatory precedent, potential approval pathways include:

• Phase 3 data readouts: Late 2026
• FDA submission (if positive): Late 2026 or early 2027
• Potential FDA approval: Second half of 2027
• International regulatory submissions would follow

These timelines remain estimates. Positive Phase 3 results with clean safety data could accelerate the process, while any unexpected findings could cause delays.

What This Means for Patients

The clinical trial evidence establishes retatrutide as the most effective weight loss medication studied to date. For patients watching this space, the data supports optimism about future treatment options while underscoring the value of currently available medications.

Tirzepatide and semaglutide offer meaningful weight loss with years of safety data and immediate availability. Starting treatment with proven options now allows patients to make progress while positioning to incorporate newer treatments as they become available.